AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Entropy Neurodynamics Ltd

0.039

+0.0012.63%

Volume:368.65K

Turnover:14.02K

Market Cap:63.61M

PE:-12.56

High:0.039

Open:0.038

Low:0.038

Close:0.038

52wk High:0.043

52wk Low:0.025

Shares:1.63B

Float Shares:878.05M

Volume Ratio:0.43

T/O Rate:0.04%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.003

EPS(LYR):-0.003

ROE:-73.07%

ROA:-40.38%

PB:8.64

PE(LYR):-12.58

Loading ...

Overview Company News Filings

Entropy Neurodynamics Granted South African Patent for Fibromyalgia Treatment Using Psilocybin

MT Newswires Live

Entropy Neurodynamics Ltd-south Africa Grants Enp Broad Fibromyalgia Patent to 2043

THOMSON REUTERS

Entropy Neurodynamics Granted Australian Patent for Psilocin Crystalline Forms

MT Newswires Live

Entropy Neurodynamics Ltd-additional Australian Patent Granted

THOMSON REUTERS

Entropy Neurodynamics' Binge Eating Disorder Drug Candidate Meets Primary Endpoint in Phase 2 Trial; Shares Gain 6%

MT Newswires Live

Entropy Neurodynamics Seeks Trading Halt

Entropy Neurodynamics - Trading Halt Pending Announcement on Binge Eating Disorder Study Data

THOMSON REUTERS

Entropy Neurodynamics Completes First-Cohort Dosing in Binge Eating Disorder Trial

MT Newswires Live

Entropy Neurodynamics Says Various Securities Due for Escrow Release; Shares Up 3%

MT Newswires Live

Entropy Neurodynamics Says Irritable Bowel Syndrome Drug Candidate Showed 75% Response Rate in Phase 2a Study; Shares Gain 3%

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.tigrgood.cn/stock/ENP.AU/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"ENP.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ENP.AU\",,,,,undefined,":{"symbol":"ENP.AU","market":"AU","secType":"STK","nameCN":"Entropy Neurodynamics Ltd","latestPrice":0.039,"timestamp":1791424243980,"preClose":0.038,"halted":0,"volume":368653,"delay":0,"changeRate":0.026315789473684233,"nameEN":"Entropy Neurodynamics Ltd","floatShares":878046607,"shares":1631064683,"eps":-0.003104,"marketStatus":"Trading","change":0.001,"latestTime":"10-08 14:37:51 AEDT","open":0.038,"high":0.039,"low":0.038,"amount":14016,"amplitude":0.026316,"askPrice":0.039,"askSize":78605,"bidPrice":0.038,"bidSize":1915906,"shortable":3,"etf":0,"ttmEps":-0.003104,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1791435600000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":0.038,"openAndCloseTimeList":[[1791414000000,1791435600000]],"volumeRatio":0.434721,"lotSize":0,"tradeCurrency":"AUD","auctionPricing":{"symbol":"ENP.AU","preClose":0.038,"auctionPrice":0.038,"auctionVolume":19652,"auctionTime":1791413959997,"referenceTime":1791369003092,"auction":1,"marketStatus":"盘前竞价","timestamp":1791413959997}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ENP.AU\",,,,,undefined,":{"symbol":"ENP.AU","floatShares":878046607,"roa":"-40.38%","roe":"-73.07%","lyrEps":-0.0031,"volumeRatio":0.434721,"shares":1631064683,"dividePrice":0,"high":0.039,"amplitude":0.026316,"preClose":0.038,"low":0.038,"week52Low":0.025,"pbRate":"8.64","psRate":"33.37","week52High":0.043,"institutionHeld":0,"latestPrice":0.039,"committee":0.921179,"eps":-0.003104,"divideRate":0,"volume":368653,"delay":0,"ttmEps":-0.003104,"open":0.038,"prevYearClose":0.033,"prevWeekClose":0.039,"prevMonthClose":0.039,"prevQuarterClose":0.039,"fiveDayClose":0.038,"twentyDayClose":0.041,"sixtyDayClose":0.035},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ENP.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ENP.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ENP.AU\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2652265468","title":"Entropy Neurodynamics Granted South African Patent for Fibromyalgia Treatment Using Psilocybin","url":"https://stock-news.laohu8.com/highlight/detail?id=2652265468","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652265468?lang=en_us&edition=fundamental","pubTime":"2026-07-20 09:25","pubTimestamp":1784510734,"startTime":"0","endTime":"0","summary":"Entropy Neurodynamics  said it was granted a patent in South Africa covering methods of treating fibromyalgia using psilocybin, with a term extended to September 2043, according to a Monday Australian bourse filing.The patent provides broad intellectual property protection covering the clinical use of psilocybin for the treatment of fibromyalgia, including therapeutic methods, dosing regimens, patient selection criteria, clinical assessment protocols, biomarkers, treatment outcome measures, integration therapy, and manufacture.The patent term is subject to the payment of annual renewal fees.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["USRD","ENP.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652500322","title":"Entropy Neurodynamics Ltd-south Africa Grants Enp Broad Fibromyalgia Patent to 2043","url":"https://stock-news.laohu8.com/highlight/detail?id=2652500322","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652500322?lang=en_us&edition=fundamental","pubTime":"2026-07-20 06:36","pubTimestamp":1784500563,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260719:nTUE1X4F4D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","ENP.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650197000","title":"Entropy Neurodynamics Granted Australian Patent for Psilocin Crystalline Forms","url":"https://stock-news.laohu8.com/highlight/detail?id=2650197000","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650197000?lang=en_us&edition=fundamental","pubTime":"2026-07-10 08:16","pubTimestamp":1783642613,"startTime":"0","endTime":"0","summary":"Entropy Neurodynamics  said the Australian Patent Office has granted it an Australian patent titled Psilocin Crystalline Forms, providing composition-of-matter protection over multiple proprietary crystalline forms of psilocin, including novel salt and cocrystal forms designed to improve its stability, solubility, and pharmaceutical properties, according to a Friday Australian bourse filing.The company said the patent claims also cover manufacturing methods, pharmaceutical formulations, and therapeutic applications across a range of neuropsychiatric disorders, with the patent remaining in force until September 2043.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XKO.AU","IOZ.AU","VAS.AU","GEAR.AU","BBOZ.AU","VAP.AU","EIGA.AU","ZYAU.AU","SLF.AU","E200.AU","BK7096","IMLC.AU","QFN.AU","GIVE.AU","XJO.AU","DACE.AU","IIGF.AU","XAO.AU","OZF.AU","ENP.AU","BEAR.AU","QRE.AU","STW.AU","OZR.AU","USRD","IISV.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650970848","title":"Entropy Neurodynamics Ltd-additional Australian Patent Granted","url":"https://stock-news.laohu8.com/highlight/detail?id=2650970848","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650970848?lang=en_us&edition=fundamental","pubTime":"2026-07-10 07:07","pubTimestamp":1783638457,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260709:nTUE4PVVPN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ENP.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649609807","title":"Entropy Neurodynamics' Binge Eating Disorder Drug Candidate Meets Primary Endpoint in Phase 2 Trial; Shares Gain 6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2649609807","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649609807?lang=en_us&edition=fundamental","pubTime":"2026-07-07 12:56","pubTimestamp":1783400177,"startTime":"0","endTime":"0","summary":"Entropy Neurodynamics  said its TRP-8803 drug candidate met the primary endpoint in the first group of a phase 2 trial in treatment-resistant binge eating disorder, with 50% of patients in complete remission and all patients seeing clinically meaningful improvement, according to a Tuesday filing with the Australian bourse.All first group patients achieved the trial's primary and secondary efficacy endpoints, experiencing a 74% reduction in binge eating episodes alongside \"significant\" improvements across symptom severity, per the filing.An independent data and safety monitoring board has approved the trial's progression to the second group, which is fully enrolled with a study baseline period to start this quarter and final results expected in the fourth quarter.The top line results also support the expansion of Entropy's precision-controlled psychedelic platform into additional neuropsychiatric indications, the company said.Shares of Entropy Neurodynamics rose past 6% in recent Tuesda","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ENP.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648639485","title":"Entropy Neurodynamics Seeks Trading Halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2648639485","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648639485?lang=en_us&edition=fundamental","pubTime":"2026-07-03 07:10","pubTimestamp":1783033804,"startTime":"0","endTime":"0","summary":"BRIEF-Entropy Neurodynamics Seeks Trading HaltJuly 3 (Reuters)-Entropy Neurodynamics LtdENP.AX:TRADING HALT PENDING ANNOUNCEMENT ON BINGE EATING DISORDER STUDY DATAFurther company coverage:ENP.AX","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260702:nFWN4340JE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ENP.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648639174","title":"Entropy Neurodynamics - Trading Halt Pending Announcement on Binge Eating Disorder Study Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2648639174","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648639174?lang=en_us&edition=fundamental","pubTime":"2026-07-03 07:09","pubTimestamp":1783033780,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260702:nFWN4340JE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","ENP.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640995148","title":"Entropy Neurodynamics Completes First-Cohort Dosing in Binge Eating Disorder Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2640995148","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640995148?lang=en_us&edition=fundamental","pubTime":"2026-06-02 09:23","pubTimestamp":1780363439,"startTime":"0","endTime":"0","summary":"Entropy Neurodynamics (ASX:ENP) said it completed dosing for all six participants in the first cohort of its phase two clinical trial of TRP-8803 for the treatment of patients with binge eating disord","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","ENP.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637367427","title":"Entropy Neurodynamics Says Various Securities Due for Escrow Release; Shares Up 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2637367427","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637367427?lang=en_us&edition=fundamental","pubTime":"2026-05-22 12:11","pubTimestamp":1779423086,"startTime":"0","endTime":"0","summary":"Entropy Neurodynamics  said a range of its restricted securities will be released from escrow on May 29, following which it will not have any securities remaining in escrow, according to a Friday filing with the Australian bourse.The securities to be released include about 49.9 million ordinary shares, as well as various options, per the filing.The company said it will apply to quote the ordinary shares within five business days after the end of the escrow period.Shares of Entropy Neurodynamics gained nearly 3% in recent Friday trade.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","ENP.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632749980","title":"Entropy Neurodynamics Says Irritable Bowel Syndrome Drug Candidate Showed 75% Response Rate in Phase 2a Study; Shares Gain 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2632749980","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632749980?lang=en_us&edition=fundamental","pubTime":"2026-05-04 13:03","pubTimestamp":1777871026,"startTime":"0","endTime":"0","summary":"Entropy Neurodynamics (ASX:ENP) said its TRP-8802 drug candidate showed a 75% response rate in a phase 2a clinical study for the treatment of irritable bowel syndrome, according to a Monday filing wit","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ENP.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":30,"code":"91000000","status":"200"}]}}